Lidocaine IV for Arrhythmia
Intravenous lidocaine is indicated primarily for hemodynamically stable monomorphic ventricular tachycardia and for shock-refractory ventricular fibrillation/pulseless ventricular tachycardia after defibrillation attempts, though amiodarone is now considered equivalent or preferred in most scenarios.
Primary Indications
Ventricular Arrhythmias (Current Guidelines)
Lidocaine may be considered for VF/pulseless VT that is unresponsive to defibrillation 1, 2. The 2018 AHA guidelines now position lidocaine alongside amiodarone as equivalent options, representing a significant shift from historical practice where lidocaine was first-line 2. This recommendation is particularly relevant for witnessed cardiac arrests where time to drug administration is shorter 2.
For hemodynamically stable monomorphic VT, lidocaine remains a reasonable option 1. However, it is classified as a "relatively weak sodium channel blocker" compared to other antiarrhythmics 1.
Important Limitation
Lidocaine has NO effect on supraventricular tachycardias (SVT) 3. Do not use it for narrow-complex tachyarrhythmias.
Dosing Regimen
Acute Treatment (Cardiac Arrest/VT)
Initial bolus: 1.0 to 1.5 mg/kg IV/IO 1, 2
- For a 70 kg patient, this equals 75-100 mg
- Can give as 100 mg bolus in cardiac arrest 3
Repeat dosing if needed:
Maintenance infusion:
- 1 to 4 mg/min (30-50 mcg/kg/min) 1
- More conservative: 2-4 mg/min 3
- For heart failure patients: limit to 1 mg/min 4
Critical Dosing Adjustments
Reduce infusion rates by 50% in:
- Patients >70 years of age 5
- Heart failure or cardiogenic shock 5
- Hepatic dysfunction 6
- Body weight <50 kg or >90 kg 7
The half-life increases dramatically in these populations: from 1-2 hours normally to >4 hours in uncomplicated MI, >20 hours in heart failure, and even longer in cardiogenic shock 5.
Maximum Dosing Limits
- Total dose over 24 hours: should not exceed 2.2 g (though this refers to amiodarone in the source) 1
- Without epinephrine: maximum 4.5 mg/kg (300 mg for average adult) 6
- Maintenance infusion should be reduced after 12-24 hours due to accumulation 5
Clinical Context and Evidence Quality
The Prophylactic Lidocaine Controversy
Historical practice favored prophylactic lidocaine for acute MI to prevent primary ventricular fibrillation. This is now Class III (not recommended) for uncomplicated MI 5. Meta-analysis showed lidocaine reduces VF by 33% but provides no mortality benefit and may increase asystole deaths 5. Prophylactic use beyond 8-12 hours increases heart failure risk (9% vs 2% with placebo) 7.
Current Position vs. Amiodarone
The 2018 AHA guidelines represent a nuanced position: while no antiarrhythmic has shown long-term survival benefit in cardiac arrest, both amiodarone and lidocaine showed improved ROSC and survival to hospital admission in the ROC-ALPS trial 2. The writing group upgraded lidocaine to equal status with amiodarone based on:
- Small increase in short-term ROSC
- Improved survival to hospital discharge in witnessed arrests 2
However, this remains a Class IIb recommendation (may be considered) - a weak recommendation reflecting limited therapeutic options beyond CPR and defibrillation 2.
Toxicity Recognition and Management
Early Warning Signs
Monitor for CNS toxicity 1, 5, 6:
- Slurred speech, altered consciousness
- Perioral numbness, dizziness
- Drowsiness, confusion
- Muscle twitching, tremor
- Seizures (late sign) 8
Cardiovascular Effects
Management: Discontinue immediately, administer benzodiazepines for seizures 8. Therapeutic levels are 1.5-5.0 μg/L 4.
Common Pitfalls
- Using lidocaine for SVT - it is ineffective 3
- Failing to reduce doses in elderly or heart failure patients - toxicity risk increases dramatically 5, 4
- Prolonged infusions without dose reduction - half-life increases after 24-48 hours 5
- Expecting immediate response in chronic VPBs - onset is delayed compared to acute arrhythmias; accurate assessment requires >8 hours 9
- Prophylactic use in uncomplicated MI - increases harm without mortality benefit 5, 7
Special Populations
Heart failure patients: Recent data suggests 1 mg/min achieves highest probability of therapeutic levels (78.6%) compared to higher rates 4. Standard PK models perform poorly in this population 4.
Elderly (>70 years): Require both reduced bolus doses and maintenance infusion rates 5.